罗替戈汀透皮贴治疗帕金森病神经精神症状的Meta分析

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo systematically evaluate the therapeutic effect of rotigotine transdermal patch in the treatment of neuropsychiatric symptoms of Parkinson′s disease(PD).Methods PubMed,Clinic trails,Cochrane Library,Embase database were searched.The search time was from database building to September 1,2017.RCT literature of rotigotine transdermal patch in the treatment of PD neuropsychiatric symptoms was collected.The inclusion and exclusion criteria were strictly followed by two investigators for independent screening of documents,extracting information and evaluating the quality,and the literature was reviewed by the third investigator.Meta-analysis was performed using RevMan 5.3 software.Results Finally,8 randomized controlled trials were included,with a total of 1675 PD patients.Meta analysis showed that,in the aspects of mood/indifference of NMSS,sleep/fatigue of BDI-Ⅱ,AS and NMSS,the scores of PDQ-8 and PDQ-39,rotigotine transdermal patch was superior to the control group,and the difference was statistically significant[emotional/indifferenceofNMSS：MD=-2.5,95%CI（-4.11,-0.89）,P=0.002;BDI-Ⅱ：MD=-1.19,95%CI（-2.30,-0.08）,P=0.04;AS：MD=-1.56,95%CI （-2.67,-0.45）,P=0.006;sleep/fatigue of NMSS：MD=-2.03,95%CI （-3.08,-0.98）,P=0.001;PDQ-8：MD=-4.93,95%CI（-6.79,-3.07）,P＜0.00001;PDQ-39：MD=-3.52,95%CI （-5.25,-1.79）,P＜0.0001].The study bias of PDSS-2 was too large.The results of SHAPS were not statistically significant[MD=-0.12,95%CI （-0.58,0.34）,P=0.61].ConclusionRotigotine Transdermal Patch can effectively improve PD neuropsychiatric symptoms and improve the quality of life of patients compared with the control group.The conclusion needs to be further studied.

Key words： Parkinson disease Rotigotine Transdermal Patch Neuropsychiatric symptoms Meta analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hao-tian
	HE Yi
	YU Gang

Cite this article:

WANG Hao-tian,HE Yi,YU Gang. Meta analysis of Rotigotine Transdermal Patches in the treatment of neuropsychiatric symptoms in the patients with Parkinson′s disease[J]. 中国当代医药, 2018, 25(7): 8-12.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I7/8

[1]	Schrag A.Psychiatric aspects of Parkinson′s disease-an update[J].J Neurol，2004，251（7）：795-804.
[2]	Aarsland D，Larsen JP，Lim NG，et al.Range of neuropsychiatric disturbances in patients with Parkinson′s disease[J].J Neurol Neurosurg Psychiatry，1999，67（4）：492-496.
[5]	Moraga-Amaro R，Gonzalez H，Pacheco R，et al.Dopamine receptor D3 deficiency results in chronic depression and anxiety[J].Behav Brain Res，2014，274：186-193.
[9]	Barone P.Neurotransmission in Parkinson′s disease：beyond dopamine[J].Eur J Neurol，2010，17（3）：364-376.
[3]	Chaudhuri KR，Healy DG，Schapira AH.Non-motor symptoms of Parkinson′s disease：diagnosis and management[J].Lancet Neurol，2006，5（3）：235-245.
[4]	Leentjens AFG，Koester J，Fruh B，et al.The effect of pramipexole on mood and motivational symptoms in Parkinson′s disease：a Meta-analysis of placebo-controlled studies[J].Clin Ther，2009，31（1）：89-98.
[6]	Liu J，Dong J，Wang L，et al.Comparative efficacy and acceptability of antidepressants in Parkinson′s disease：a network Meta-analysis[J].PLoS One，2013，8（10）：e76651.
[7]	Elshoff JP，Cawello W，Andreas JO，et al.An update on pharmacological，pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson′s disease and restless legs syndrome[J].Drugs，2015，75（5）：487-501.
[8]	Elshoff JP，Braun M，Andreas JO，et al.Steady-state plasma concentration profile of transdermal rotigotine：an integrated analysis of three，open-label，randomized，phase Ⅰ multiple dose studies[J].Clin Ther，2012，34（4）：966-978.
[10]	Antonini A，Bauer L，Dohin E，et al.Effects of rotigotine transdermal patch in patients with Parkinson′s disease presenting with non-motor symptoms-results of a double-blind，randomized，placebo-controlled trial[J].Eur J Neurol，2015，22（10）：1400-1407.
[11]	Bhidayasiri R，Sringean J，Chaiwong S，et al.Rotigotine for nocturnal hypokinesia in Parkinson′s disease：quantitative analysisofefficacyfromarandomized，placebo-controlledtrial using an axial inertial sensor[J].Parkinsonism Relat Disord，2017，44：124-128.
[12]	Chung SJ，Asgharnejad M，Bauer L，et al.Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson′s disease[J].Expert Opin Pharmacother，2016，17（11）：1453-1461.
[13]	Hauser RA，Slawek J，Barone P，et al.Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson′s disease[J].BMC Neurol，2016，16（1）：90.
[14]	Mizuno Y，Nomoto M，Hasegawa K，et al.Rotigotine vs ropinirole in advanced stage Parkinson′s disease：a double-blind study[J].Park Relat Disord，2014，20（12）：1388-1393.
[15]	Poewe WH，Rascol O，Quinn N，et al.Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson′s disease：adouble-blind，double-dummy，randomised controlled trial[J].Lancet Neurol，2007，6（6）：513-520.
[16]	Rascol O，Zesiewicz T，Chaudhuri KR，et al.A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on parkinson′s disease-associated chronic pain[J].J Clin Pharmacol，2016，56（7）：852-861.
[17]	Trenkwalder C，Kies B，Rudzinska M，et al.Rotigotine effects on early morning motor function and sleep in Parkinson′s disease：A double-blind，randomized，placebo-controlled study （RECOVER）[J].Mov Disord，2011，26（1）：90-99.